Youlin Pharma Secures Over RMB 100 Million in Series A+ Financing Led by Zhongding Capital

VCBeat (WeChat ID: vcbeat) recently learned that Shanghai Youlin Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Youlin Pharma”) announced the completion of its Series A+ financing round, exceeding RMB 100 million.Led by Zhongding Capital, with continued increased investment from existing shareholder Qianji Capital, and followed by Renjin Investment. This round of financing will accelerate the development and deployment of digital clinical trial systems, as well as expand the professional clinical services team.

Regarding the acquisition of this round of financing,Mr. Wang Junlin, Founder and Chairman of Youlin Medicine“We extend our sincere gratitude to both new and existing investors for their recognition of the Youlin team. As a core component of new drug development, clinical research presents numerous opportunities and challenges. The clinical development of novel oncology drugs demands immediate high-intensity effort from the outset, creating an urgent need for innovative clinical service capabilities. Youlin is committed to leveraging digital clinical trial systems to enhance efficiency for research centers and investigators, while providing sponsors with proactive, specialized, and one-stop clinical services that meet the dynamic decision-making needs of new drug development, thereby delivering value to our clients.”

Youlin Medicine, established in 2017, is a digital clinical research organization (CRO) focused on the oncology field. The company leverages intelligent technologies to provide clients with integrated clinical research services spanning from strategy to execution. Service offerings include: site management services, clinical strategy consulting, protocol design, clinical monitoring, biostatistics, data management, bioanalysis, and third-party medical imaging assessment.

Traditional CRO companies still rely on manual data entry and manual monitoring management; this labor-intensive approach inevitably increases the cost of clinical trials. Youlin Medicine addresses this pain point by leveraging an Intelligent Clinical Research Management System combined with embedded SMO services.

The eDISC system, developed by Youlin Medicine, is an intelligent collaborative platform for clinical research that integrates artificial intelligence, big data, and cloud technologies. Embedded within clinical research centers to enhance operational efficiency, the platform enables precise subject recruitment, automated clinical research data capture, intelligent guidance for site operations, and real-time online collaboration across multiple sites. This reduces data error rates, lowers clinical research costs, and improves the quality of trial projects. Furthermore, by integrating with traditional clinical operational services throughout the entire trial process, the platform truly achieves end-to-end delivery from study protocol to high-quality clinical research outcomes.

Currently, Lin Yiyao’s intelligent clinical trial system has been delivered and is operational at multiple centers, with plans to collaborate with more than 30 research centers in the future.

Lead Investor in This RoundZhu Yingchun, Partner at Zhongding Capital“Zhongding has long focused on how digitalization empowers various industries and enhances efficiency. We are deeply impressed by Youlin’s digital infrastructure and its specialized service capabilities in the oncology field. Clinical trials are characterized by lengthy processes, numerous milestones, heavy reliance on manual labor, and the need for multi-party collaboration. Through its self-developed digital system for clinical trials, Youlin efficiently empowers all stakeholders in clinical research, significantly improving the execution efficiency of clinical trial protocols. Furthermore, by implementing end-to-end digitalization, it achieves a leap in data quality and enables dynamic, remote, and multi-center intelligent collaboration, representing a digital revolution against the traditional, labor-intensive CRO model. We firmly believe that Youlin is poised to become China’s leading 2.0 new drug clinical CRO, leveraging its high-efficiency delivery system driven by digitalization and its professional service capabilities in the oncology sector.”

In this round, existing shareholder Qianji Capital continued to increase its stake.Wu Hai, Partner at Qianji Capitalstated: “As a Series A investor in Youlin, Qianji Capital has long been bullish on the broad sector of new drug development. Youlin is a leading enterprise in China that empowers clinical research for novel oncology drugs with digital tools and has successfully implemented these solutions in practice. Mr. Wang Junlin, the founder, possesses profound insights into the industry, and the team has demonstrated exceptional execution capabilities over the past six months. We firmly believe that digitalization will bring about significant transformation and enhancement to China’s healthcare industry in the future. We will continue to support Youlin’s long-term development, helping it become a highly competitive leader in this field.”

Ms. Liang Jianping, Executive Partner of Renjin Investment“Currently, 60% of innovative drugs in China are new anti-tumor agents. The research and development (R&D) of innovative oncology drugs is a field with high technical barriers, presenting numerous challenges during clinical trials. Youlin Medicine is a clinical CRO specializing in the oncology sector, dedicated to accelerating every stage of clinical research for new anti-tumor drugs, thereby helping pharmaceutical companies make scientific decisions and control early-stage R&D costs. Renjin Investment has consistently adhered to a strategy of comprehensive layout across the entire biomedical industry chain. Its investment in Youlin Medicine also carries strategic significance, and it will collaborate with Youlin Medicine in the future to facilitate the successful market launch of more innovative anti-tumor drugs.”

Zhongding Capital, established in 2010, is an ecosystem-focused fund dedicated to “enhancing industrial efficiency through core supply chain capabilities.” Its investment focus spans logistics & supply chain, retail & branding, and data technology. Over its ten-year history, Zhongding Capital has grown its fund size to RMB 13 billion, invested in 130 companies, and helped 15 of them become unicorns, establishing itself as the most influential venture capital firm in China’s logistics and supply chain sector.

Qianji Capital, specializing in venture capital and private equity investment in the life sciences and healthcare industries, is one of China’s earliest professional healthcare-focused investment funds. It is committed to promoting the transformation, upgrading, and innovation of China’s healthcare industry. Qianji Capital currently manages five healthcare industry funds, with capital commitments from renowned international and domestic institutional investors, including Asian sovereign wealth funds, government agencies, domestic and foreign insurance and financial institutions, and multinational corporations. The firm has invested in numerous leading enterprises in the healthcare and life sciences sectors.

Renjin Investment focuses primarily on the healthcare industry, while also covering TMT, environmental protection, new energy, and high-end equipment manufacturing. Its investment activities span all stages, including M&A, private equity (PE), venture capital (VC), and angel investments. Currently, all its portfolio companies are profitable and have successfully achieved industrial implementation. As a representative case, Renjin’s investment in Venus Medtech achieved substantial returns by listing in the same year it was invested.